FI104255B - Menetelmä ihmisen seerumialbumiinin N-terminaalifragmentteja sisältävien fuusioproteiinien valmistamiseksi - Google Patents

Menetelmä ihmisen seerumialbumiinin N-terminaalifragmentteja sisältävien fuusioproteiinien valmistamiseksi Download PDF

Info

Publication number: FI104255B
Authority: FI; Finland
Prior art keywords: hsa; variant; sequence; polypeptide; terminal
Prior art date: 1989-04-29

Application number

FI915073A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI915073A0 (fi

FI104255B1 (fi

Inventor

David James Ballance

Original Assignee

Delta Biotechnology Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-29

Filing date

1991-10-28

Publication date

1999-12-15

1991-10-28 Application filed by Delta Biotechnology Ltd filed Critical Delta Biotechnology Ltd

1991-10-28 Publication of FI915073A0 publication Critical patent/FI915073A0/fi

1999-12-15 Application granted granted Critical

1999-12-15 Publication of FI104255B1 publication Critical patent/FI104255B1/fi

1999-12-15 Publication of FI104255B publication Critical patent/FI104255B/fi

Links

238000000034 method Methods 0.000 title claims description 13
102000008100 Human Serum Albumin Human genes 0.000 title description 7
108091006905 Human Serum Albumin Proteins 0.000 title description 7
108020001507 fusion proteins Proteins 0.000 title description 5
102000037865 fusion proteins Human genes 0.000 title description 5
238000002360 preparation method Methods 0.000 title description 3
210000004898 n-terminal fragment Anatomy 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 claims description 36
229920001184 polypeptide Polymers 0.000 claims description 35
102000004196 processed proteins & peptides Human genes 0.000 claims description 35
230000004927 fusion Effects 0.000 claims description 18
108010067306 Fibronectins Proteins 0.000 claims description 17
102000016359 Fibronectins Human genes 0.000 claims description 17
101001027128 Homo sapiens Fibronectin Proteins 0.000 claims description 9
210000004899 c-terminal region Anatomy 0.000 claims description 6
210000004027 cell Anatomy 0.000 claims description 4
239000002773 nucleotide Substances 0.000 claims description 4
125000003729 nucleotide group Chemical group 0.000 claims description 4
102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
102000015395 alpha 1-Antitrypsin Human genes 0.000 claims description 3
108010050122 alpha 1-Antitrypsin Proteins 0.000 claims description 3
229940024142 alpha 1-antitrypsin Drugs 0.000 claims description 3
239000003102 growth factor Substances 0.000 claims description 3
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
239000002157 polynucleotide Substances 0.000 claims 2
102000040430 polynucleotide Human genes 0.000 claims 2
108091033319 polynucleotide Proteins 0.000 claims 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
150000001413 amino acids Chemical group 0.000 description 26
239000012634 fragment Substances 0.000 description 23
235000001014 amino acid Nutrition 0.000 description 22
229940024606 amino acid Drugs 0.000 description 21
108091034117 Oligonucleotide Proteins 0.000 description 20
239000013612 plasmid Substances 0.000 description 18
108020004414 DNA Proteins 0.000 description 17
108020004705 Codon Proteins 0.000 description 13
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 13
108091028043 Nucleic acid sequence Proteins 0.000 description 11
108091026890 Coding region Proteins 0.000 description 8
241000588724 Escherichia coli Species 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
230000028327 secretion Effects 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000010276 construction Methods 0.000 description 5
238000012300 Sequence Analysis Methods 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
239000002299 complementary DNA Substances 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000002245 particle Substances 0.000 description 4
230000007017 scission Effects 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
239000013598 vector Substances 0.000 description 4
239000004475 Arginine Substances 0.000 description 3
108010014173 Factor X Proteins 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
230000002194 synthesizing effect Effects 0.000 description 3
241001515965 unidentified phage Species 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
PMKKIDFHWBBGDA-UHFFFAOYSA-N 2-(2,5-dioxopyrrol-1-yl)ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCN1C(=O)C=CC1=O PMKKIDFHWBBGDA-UHFFFAOYSA-N 0.000 description 2
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
108090000144 Human Proteins Proteins 0.000 description 2
102000003839 Human Proteins Human genes 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
235000009582 asparagine Nutrition 0.000 description 2
229960001230 asparagine Drugs 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000013519 translation Methods 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
241000228245 Aspergillus niger Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000016844 Immunoglobulin-like domains Human genes 0.000 description 1
108050006430 Immunoglobulin-like domains Proteins 0.000 description 1
241000235649 Kluyveromyces Species 0.000 description 1
241001138401 Kluyveromyces lactis Species 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
101150019648 PKG gene Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000235648 Pichia Species 0.000 description 1
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
102000007584 Prealbumin Human genes 0.000 description 1
108010071690 Prealbumin Proteins 0.000 description 1
241000235070 Saccharomyces Species 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
238000007792 addition Methods 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
-1 amino- Chemical class 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000001659 chemokinetic effect Effects 0.000 description 1
230000003399 chemotactic effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000004020 conductor Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
239000012467 final product Substances 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
YQNQTEBHHUSESQ-UHFFFAOYSA-N lithium aluminate Chemical compound [Li+].[O-][Al]=O YQNQTEBHHUSESQ-UHFFFAOYSA-N 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
239000000047 product Substances 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

FI915073A 1989-04-29 1991-10-28 Menetelmä ihmisen seerumialbumiinin N-terminaalifragmentteja sisältävien fuusioproteiinien valmistamiseksi FI104255B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB898909916A GB8909916D0 (en)	1989-04-29	1989-04-29	Polypeptides
GB8909916		1989-04-29
PCT/GB1990/000650 WO1990013653A1 (fr)	1989-04-29	1990-04-26	Proteines de fusion contenant des fragments n-terminaux de l'albumine serale humaine (hsa)
GB9000650		1990-04-26

Publications (3)

Publication Number	Publication Date
FI915073A0 FI915073A0 (fi)	1991-10-28
FI104255B1 FI104255B1 (fi)	1999-12-15
FI104255B true FI104255B (fi)	1999-12-15

Family

ID=10656000

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI915073A FI104255B (fi)	1989-04-29	1991-10-28	Menetelmä ihmisen seerumialbumiinin N-terminaalifragmentteja sisältävien fuusioproteiinien valmistamiseksi

Country Status (12)

Country	Link
EP (1)	EP0470165A1 (fr)
JP (1)	JP2781459B2 (fr)
KR (1)	KR100227167B1 (fr)
AU (1)	AU630450B2 (fr)
CA (1)	CA2015687C (fr)
FI (1)	FI104255B (fr)
GB (2)	GB8909916D0 (fr)
HU (1)	HUT61049A (fr)
IE (1)	IE67651B1 (fr)
IL (1)	IL94243A (fr)
WO (1)	WO1990013653A1 (fr)
ZA (1)	ZA903237B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5610148A (en) *	1991-01-18	1997-03-11	University College London	Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) *	1991-01-18	1997-05-13	University College London	Depot formulations
FR2686899B1 (fr) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686900B1 (fr) *	1992-01-31	1995-07-21	Rhone Poulenc Rorer Sa	Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
WO1994016085A2 (fr) *	1992-12-30	1994-07-21	Zymogenetics, Inc.	Proteines hybrides presentant des activites de reticulation et de liaison tissulaire
GB9408466D0 (en) *	1994-04-27	1994-06-22	Univ Nottingham	Cloning and functional expression of neurotoxins
US5543308A (en) *	1994-10-18	1996-08-06	New England Biolabs, Inc.	Isolated DNA encoding the FSEI restriction endonuclease and related methods for producing the same
US7112320B1 (en)	1995-06-07	2006-09-26	Andre Beaulieu	Solid wound healing formulations containing fibronectin
US5877149A (en)	1995-06-07	1999-03-02	Beaulieu; Andre	Deepithelialized skin diffusion cell system
US5641483A (en) *	1995-06-07	1997-06-24	Beaulieu; Andre	Wound healing formulations containing human plasma fibronectin
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
US6423512B1 (en)	1996-07-26	2002-07-23	Novartis Ag	Fusion polypeptides
AR008077A1 (es) *	1996-07-26	1999-12-09	Talarico Salinas Laura Beatriz	Un polipeptido de fusion o una sal del mismo, su uso, un proceso para prepararlos, una composicion farmaceutica que los comprende, y un vector.
US5932693A (en) *	1996-12-10	1999-08-03	Washington University	Antithrombotic peptides
AU2149899A (en)	1998-01-23	1999-08-09	Novo Nordisk A/S	Process for making desired polypeptides in yeast
DE69933216T2 (de)	1998-06-15	2007-09-20	GTC Biotherapeutics, Inc., Framingham	Erythropoietin-analog-menschliches serum-albumin fusionsprotein
EP2213743A1 (fr) *	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US7507413B2 (en)	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
KR100888915B1 (ko)	2001-08-15	2009-03-16	다카라 바이오 가부시키가이샤	항원특이적 세포상해성 ｔ 세포 확대배양방법
WO2005003296A2 (fr)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Proteines hybrides d'albumine
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
JP4406566B2 (ja)	2002-03-25	2010-01-27	タカラバイオ株式会社	細胞傷害性リンパ球の製造方法
KR101331746B1 (ko) *	2003-08-22	2013-11-20	다카라 바이오 가부시키가이샤	세포 상해성 림프구의 제조 방법
US7850970B2 (en)	2003-08-26	2010-12-14	The Regents Of The University Of Colorado	Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
GB0329681D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Gene expression technique
US9057061B2 (en)	2003-12-23	2015-06-16	Novozymes Biopharma Dk A/S	Gene expression technique
WO2006067511A1 (fr)	2004-12-23	2006-06-29	Novozymes Delta Limited	Technique d'expression genetique
GB0329722D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Modified plasmid and use thereof
EP1816201A1 (fr)	2006-02-06	2007-08-08	CSL Behring GmbH	Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée
WO2007146038A2 (fr)	2006-06-07	2007-12-21	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
EP2049560B1 (fr)	2006-07-13	2013-05-15	Novozymes Biopharma DK A/S	Procédé de fabrication de particules d'un matériau protéique
KR101722961B1 (ko)	2009-02-11	2017-04-04	알부메딕스 에이/에스	알부민 변이체 및 접합체
EP2493921B1 (fr)	2009-10-30	2018-09-26	Albumedix Ltd	Variants d'albumine
EP2556087A1 (fr)	2010-04-09	2013-02-13	Novozymes Biopharma DK A/S	Dérivés et variants d'albumine
WO2012178102A2 (fr) *	2011-06-24	2012-12-27	The Regents Of The Unversity Of Colorado, A Body Corporate	Compositions, procédés et utilisations de molécules de fusion de l'alpha-1 antitrypsine
EP2780364A2 (fr)	2011-11-18	2014-09-24	Eleven Biotherapeutics, Inc.	Protéines ayant une demi-vie et d'autres propriétés améliorées
DK2825556T3 (en)	2012-03-16	2018-04-16	Albumedix As	albumin Variants
MX2015005363A (es)	2012-11-08	2015-11-06	Novozymes Biopharma Dk As	Variantes de albumina.
EP2968587A2 (fr)	2013-03-13	2016-01-20	Bristol-Myers Squibb Company	Domaines d'échafaudage à base de fibronectine liés à une sérum albumine ou fragment se liant à celle-ci
JP7007261B2 (ja)	2015-08-20	2022-01-24	アルブミディクスリミティド	アルブミン変異体及びコンジュゲート
WO2018089702A1 (fr) *	2016-11-10	2018-05-17	Keros Therapeutics, Inc.	Polypeptides de fusion gdnf et leurs procédés d'utilisation
CA3117961A1 (fr) *	2018-10-29	2020-05-07	Spin Therapeutics, Llc	Compositions et methodes pour les dereglements de l'alpha-1 antitrypsine
EP3711772A1 (fr)	2019-03-20	2020-09-23	Oslo Universitetssykehus HF	Protéines recombinantes et protéines de fusion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE459586B (sv) *	1987-09-14	1989-07-17	Mta Szegedi Biolog Koezponti	Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
GB8725529D0 (en) *	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides

1989
- 1989-04-29 GB GB898909916A patent/GB8909916D0/en active Pending
1990
- 1990-04-26 HU HU904413A patent/HUT61049A/hu unknown
- 1990-04-26 WO PCT/GB1990/000650 patent/WO1990013653A1/fr not_active Ceased
- 1990-04-26 EP EP90907285A patent/EP0470165A1/fr active Pending
- 1990-04-26 AU AU55646/90A patent/AU630450B2/en not_active Expired
- 1990-04-26 JP JP2506978A patent/JP2781459B2/ja not_active Expired - Lifetime
- 1990-04-27 IE IE155490A patent/IE67651B1/en not_active IP Right Cessation
- 1990-04-27 ZA ZA903237A patent/ZA903237B/xx unknown
- 1990-04-27 CA CA002015687A patent/CA2015687C/fr not_active Expired - Lifetime
- 1990-04-29 IL IL9424390A patent/IL94243A/en not_active IP Right Cessation
1991
- 1991-09-06 GB GB9119043A patent/GB2246783B/en not_active Expired - Lifetime
- 1991-10-14 KR KR1019910701334A patent/KR100227167B1/ko not_active Expired - Fee Related
- 1991-10-28 FI FI915073A patent/FI104255B/fi active

Also Published As

Publication number	Publication date
GB8909916D0 (en)	1989-06-14
HU904413D0 (en)	1992-01-28
FI915073A0 (fi)	1991-10-28
HUT61049A (en)	1992-11-30
WO1990013653A1 (fr)	1990-11-15
IL94243A (en)	1995-10-31
KR920701451A (ko)	1992-08-11
EP0470165A1 (fr)	1992-02-12
GB2246783B (en)	1992-10-14
IE901554L (en)	1990-10-29
AU5564690A (en)	1990-11-29
IL94243A0 (en)	1991-01-31
FI104255B1 (fi)	1999-12-15
GB2246783A (en)	1992-02-12
JPH04506598A (ja)	1992-11-19
JP2781459B2 (ja)	1998-07-30
ZA903237B (en)	1991-03-27
AU630450B2 (en)	1992-10-29
CA2015687C (fr)	2000-08-29
KR100227167B1 (ko)	1999-10-15
GB9119043D0 (en)	1991-12-04
IE67651B1 (en)	1996-04-17
CA2015687A1 (fr)	1990-10-29

Legal Events

Date

Code

Title

Description

2007-05-08

PC

Transfer of assignment of patent

Owner name: NOVOZYMES DELTA LIMITED

Free format text: NOVOZYMES DELTA LIMITED

2009-02-25

PC